-
1
-
-
70450190156
-
-
Canadian Cancer Society, National Cancer Institute of Canada, Statistics Canada, Provincial/Terretorial Cancer Registries, and Health Canada. Canadian Cancer Statistics 2004.
-
Canadian Cancer Statistics 2004
-
-
-
2
-
-
33745300707
-
What is cancer?
-
Steen, G., Mirro, J., Eds. (Perseus Publishing, Cambridge)
-
Steen, R.G. What is cancer? In Childhood Cancer: A Handbook from St. Jude Children's Research Hospital, Steen, G., Mirro, J., Eds. (Perseus Publishing, Cambridge, 2000), 3-10.
-
(2000)
Childhood Cancer: A Handbook from St. Jude Children's Research Hospital
, pp. 3-10
-
-
Steen, R.G.1
-
3
-
-
33745319873
-
Pharmacology of cancer chemotherapy in paediatrics: Feasibility and ethical considerations in phase I trials
-
Koren, G., Diav-Citrin, O., Eds. (Bailliere Tindall, London)
-
Baruchel, S.; Rowell, M. Pharmacology of cancer chemotherapy in paediatrics: feasibility and ethical considerations in phase I trials. In Paediatric Pharmacology: Towards Evidence-Based Drug Therapy. Koren, G., Diav-Citrin, O., Eds. (Bailliere Tindall, London, 1998), 439-453.
-
(1998)
Paediatric Pharmacology: Towards Evidence-Based Drug Therapy
, pp. 439-453
-
-
Baruchel, S.1
Rowell, M.2
-
4
-
-
0003800704
-
-
National Cancer Institute of Canada: Cancer Statistics 2000, Toronto, Canada
-
Canadian Cancer Statistics. Canadian Cancer Statistics 2000 - Cancer in Children aged 0-19 years. National Cancer Institute of Canada: Cancer Statistics 2000, Toronto, Canada, 2000. Accessed June 22nd, 2005. Online: http://www.cancer.ca/stats2000.childe.htm.
-
(2000)
Canadian Cancer Statistics 2000 - Cancer in Children Aged 0-19 Years
-
-
-
5
-
-
0033038974
-
The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
-
Capizzi, R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin. Oncol. 1999, 26, 3-21.
-
(1999)
Semin. Oncol.
, vol.26
, pp. 3-21
-
-
Capizzi, R.L.1
-
6
-
-
0001828579
-
Late effects of childhood cancer and its treatment
-
Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia)
-
Blatt, J.; Copeland, D.R.; Bleyer, W.A. Late effects of childhood cancer and its treatment. In Principles and Practice of Pediatric Oncology. Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia, 1997), 1303-1329.
-
(1997)
Principles and Practice of Pediatric Oncology
, pp. 1303-1329
-
-
Blatt, J.1
Copeland, D.R.2
Bleyer, W.A.3
-
7
-
-
0037458325
-
Minimizing long-term tumor burden: The logic for metronomic chemotherapeutic dosing and its antiangiogenic basis
-
Hahnfeldt, P.; Folkman, J.; Hlatky, L. Minimizing long-term tumor burden: the logic for metronomic chemotherapeutic dosing and its antiangiogenic basis. J. Theor. Biol. 2003, 220, 545-554.
-
(2003)
J. Theor. Biol.
, vol.220
, pp. 545-554
-
-
Hahnfeldt, P.1
Folkman, J.2
Hlatky, L.3
-
8
-
-
11444266441
-
Cancer anti-angiogenic therapy
-
Shimizu, K.;Oku, N. Cancer anti-angiogenic therapy. Biol. Pharm. Bull. 2004, 27, 599-605.
-
(2004)
Biol. Pharm. Bull.
, vol.27
, pp. 599-605
-
-
Shimizu, K.1
Oku, N.2
-
9
-
-
0035865363
-
Redefining the target: Chemotherapeutics as antiangiogenics
-
Miller, K.D.; Sweeney, C.J.; Sledge, G.W.; Jr. Redefining the target: chemotherapeutics as antiangiogenics. J. Clin. Oncol. 2001, 19, 1195-1206.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1195-1206
-
-
Miller, K.D.1
Sweeney, C.J.2
Sledge Jr., G.W.3
-
10
-
-
0034161989
-
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies
-
Eberhard, A.; Kahlert, S.; Goede, V.; Hemmerlein, B.; Plate, K.H.; Augustin, H.G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res. 2000, 60, 1388-1393.
-
(2000)
Cancer Res.
, vol.60
, pp. 1388-1393
-
-
Eberhard, A.1
Kahlert, S.2
Goede, V.3
Hemmerlein, B.4
Plate, K.H.5
Augustin, H.G.6
-
11
-
-
0034087691
-
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
-
Klement, G.; Baruchel, S.; Rak, J.; Man, S.; Clark, K.; Hicklin, D.J.; Bohlen, P.; Kerbel, R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 2000, 105, R15-R24.
-
(2000)
J. Clin. Invest.
, vol.105
-
-
Klement, G.1
Baruchel, S.2
Rak, J.3
Man, S.4
Clark, K.5
Hicklin, D.J.6
Bohlen, P.7
Kerbel, R.S.8
-
12
-
-
0034032882
-
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
-
Browder, T.; Butterfield, C.E.; Kraling, B.M.; Shi, B.; Marshall, B.; O'Reilly, M.S.; Folkman, J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000, 60, 1878-1886.
-
(2000)
Cancer Res.
, vol.60
, pp. 1878-1886
-
-
Browder, T.1
Butterfield, C.E.2
Kraling, B.M.3
Shi, B.4
Marshall, B.5
O'Reilly, M.S.6
Folkman, J.7
-
13
-
-
85013312416
-
Tumor angiogenesis: Therapeutic implications
-
Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971, 285, 1182-1186.
-
(1971)
N. Engl. J. Med.
, vol.285
, pp. 1182-1186
-
-
Folkman, J.1
-
14
-
-
0025141337
-
What is the evidence that tumors are angiogenesis dependent?
-
Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 1990, 82, 4-6.
-
(1990)
J. Natl. Cancer Inst.
, vol.82
, pp. 4-6
-
-
Folkman, J.1
-
15
-
-
2942615257
-
The anti-angiogenic basis of metronomic chemotherapy
-
Kerbel, R.S.; Kamen, B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 2004, 4, 423-436.
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 423-436
-
-
Kerbel, R.S.1
Kamen, B.A.2
-
16
-
-
0025717523
-
Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
-
Kerbel, R.S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991, 13, 31-36.
-
(1991)
Bioessays
, vol.13
, pp. 31-36
-
-
Kerbel, R.S.1
-
17
-
-
16844381577
-
A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities
-
Hida, K.; Klagsbrun, M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65, 2507-2510.
-
(2005)
Cancer Res.
, vol.65
, pp. 2507-2510
-
-
Hida, K.1
Klagsbrun, M.2
-
18
-
-
14644446018
-
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
-
Pietras, K.; Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23, 939-952.
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 939-952
-
-
Pietras, K.1
Hanahan, D.2
-
19
-
-
0034048358
-
Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
-
Hanahan, D.; Bergers, G.; Bergsland, E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J. Clin. Invest. 2000, 105, 1045-1047.
-
(2000)
J. Clin. Invest.
, vol.105
, pp. 1045-1047
-
-
Hanahan, D.1
Bergers, G.2
Bergsland, E.3
-
20
-
-
0028087294
-
Cyclophosphamide-induced lung toxicity: Mechanism of endothelial cell injury
-
Kachel, D.L.; Martin, W.J. Cyclophosphamide-induced lung toxicity: mechanism of endothelial cell injury. J. Pharmacol. Exp. Ther. 1994, 268, 42-46.
-
(1994)
J. Pharmacol. Exp. Ther.
, vol.268
, pp. 42-46
-
-
Kachel, D.L.1
Martin, W.J.2
-
21
-
-
0026753046
-
The effects of 5-fluorouracil and mitomycin C on the corneal endothelium
-
Nuyts, R.M.; Pels, E.; Greve, E. L. The effects of 5-fluorouracil and mitomycin C on the corneal endothelium. Curr. Eye. Res. 1992, 11, 565-570.
-
(1992)
Curr. Eye. Res.
, vol.11
, pp. 565-570
-
-
Nuyts, R.M.1
Pels, E.2
Greve, E.L.3
-
22
-
-
0028839115
-
Toxicity of mitomycin C toward cultured pulmonary artery endothelium
-
Hoorn, C.M.; Wagner, J.G.; Petry, T.W.; Roth, R.A. Toxicity of mitomycin C toward cultured pulmonary artery endothelium. Toxicol. Appl. Pharmacol. 1995, 130, 87-94.
-
(1995)
Toxicol. Appl. Pharmacol.
, vol.130
, pp. 87-94
-
-
Hoorn, C.M.1
Wagner, J.G.2
Petry, T.W.3
Roth, R.A.4
-
23
-
-
0026444990
-
Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay
-
Steiner, R. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. EXS 1992, 61, 449-454.
-
(1992)
EXS
, vol.61
, pp. 449-454
-
-
Steiner, R.1
-
24
-
-
0842311624
-
Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma
-
Yule, S.M.; Price, L.; McMahon, A.D.; Pearson, A.D.; Boddy, A.V. Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin. Cancer Res. 2004, 10, 455-460.
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 455-460
-
-
Yule, S.M.1
Price, L.2
McMahon, A.D.3
Pearson, A.D.4
Boddy, A.V.5
-
25
-
-
0025793698
-
Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism
-
Baguley, B.C.; Holdaway, K.M.; Thomsen, L.L.; Zhuang, L.; Zwi, L.J. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer 1991, 27, 482-487.
-
(1991)
Eur. J. Cancer
, vol.27
, pp. 482-487
-
-
Baguley, B.C.1
Holdaway, K.M.2
Thomsen, L.L.3
Zhuang, L.4
Zwi, L.J.5
-
26
-
-
0029802685
-
The microtubule-affecting drug paclitaxel has antiangiogenic activity
-
Belotti, D.; Vergani, V.; Drudis, T.; Borsotti, P.; Pitelli, M.R.; Viale, G.; Giavazzi, R.; Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 1996, 2, 1843-1849.
-
(1996)
Clin. Cancer Res.
, vol.2
, pp. 1843-1849
-
-
Belotti, D.1
Vergani, V.2
Drudis, T.3
Borsotti, P.4
Pitelli, M.R.5
Viale, G.6
Giavazzi, R.7
Taraboletti, G.8
-
27
-
-
0031015504
-
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol
-
Klauber, N.; Parangi, S.; Flynn, E.; Hamel, E.; D'Amato, R.J. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res. 1997, 57, 81-86.
-
(1997)
Cancer Res.
, vol.57
, pp. 81-86
-
-
Klauber, N.1
Parangi, S.2
Flynn, E.3
Hamel, E.4
D'Amato, R.J.5
-
28
-
-
0032930199
-
Paclitaxel (Taxol): An inhibitor of angiogenesis in a highly vascularized transgenic breast cancer
-
Lau, D.H.; Xue, L.; Young, L.J.; Burke, P.A.; Cheung, A.T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm. 1999, 14, 31-36.
-
(1999)
Cancer Biother. Radiopharm.
, vol.14
, pp. 31-36
-
-
Lau, D.H.1
Xue, L.2
Young, L.J.3
Burke, P.A.4
Cheung, A.T.5
-
29
-
-
0033563116
-
Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process
-
Presta, M.; Rusnati, M.; Belleri, M.; Morbidelli, L.; Ziche, M.; Ribatti, D. Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 1999, 59, 2417-2424.
-
(1999)
Cancer Res.
, vol.59
, pp. 2417-2424
-
-
Presta, M.1
Rusnati, M.2
Belleri, M.3
Morbidelli, L.4
Ziche, M.5
Ribatti, D.6
-
30
-
-
0032956544
-
Antiangiogenic effects of camptothecin analogues 9-amino-20(S)- camptothecin, topotecan, and CPT-11 studied in the mouse cornea model
-
O'Leary, J.J.; Shapiro, R.L.; Ren, C.J.; Chuang, N.; Cohen, H.W.; Potmesil, M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 1999, 5, 181-187.
-
(1999)
Clin. Cancer Res.
, vol.5
, pp. 181-187
-
-
O'Leary, J.J.1
Shapiro, R.L.2
Ren, C.J.3
Chuang, N.4
Cohen, H.W.5
Potmesil, M.6
-
31
-
-
0032532391
-
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4
-
Iyer, S.; Chaplin, D.J.; Rosenthal, D.S.; Boulares, A.M.; Li, L.Y.; Smulson, M.E. Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res. 1998, 58, 4510-4514.
-
(1998)
Cancer Res.
, vol.58
, pp. 4510-4514
-
-
Iyer, S.1
Chaplin, D.J.2
Rosenthal, D.S.3
Boulares, A.M.4
Li, L.Y.5
Smulson, M.E.6
-
32
-
-
0032950870
-
Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A4 phosphate
-
Chaplin, D.J.; Pettit, G.R.; Hill, S.A. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999, 19, 189-195.
-
(1999)
Anticancer Res.
, vol.19
, pp. 189-195
-
-
Chaplin, D.J.1
Pettit, G.R.2
Hill, S.A.3
-
33
-
-
27644436870
-
The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
-
Shaked, Y.; Emmenegger, U.; Man, S.; Cervi, D.; Bertolini, F.; Ben David, Y.; Kerbel, R.S. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. 2005, Blood.
-
(2005)
Blood
-
-
Shaked, Y.1
Emmenegger, U.2
Man, S.3
Cervi, D.4
Bertolini, F.5
Ben David, Y.6
Kerbel, R.S.7
-
34
-
-
20944436688
-
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: Implications for use as a surrogate marker of antiangiogenic activity
-
Beaudry, P.; Force, J.; Naumov, G.N.; Wang, A.; Baker, C.H.; Ryan, A.; Soker, S.; Johnson, B.E.; Folkman, J.; Heymach, J.V. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res. 2005, 11, 3514-3522.
-
(2005)
Clin Cancer Res.
, vol.11
, pp. 3514-3522
-
-
Beaudry, P.1
Force, J.2
Naumov, G.N.3
Wang, A.4
Baker, C.H.5
Ryan, A.6
Soker, S.7
Johnson, B.E.8
Folkman, J.9
Heymach, J.V.10
-
35
-
-
0029092874
-
Aspirin and reduced risk of esophageal carcinoma
-
Funkhouser, E.M.; Sharp, G.B. Aspirin and reduced risk of esophageal carcinoma. Cancer 1995, 76, 1116-1119.
-
(1995)
Cancer
, vol.76
, pp. 1116-1119
-
-
Funkhouser, E.M.1
Sharp, G.B.2
-
36
-
-
0242331613
-
Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy
-
U.S.A.
-
Bocci, G.; Francia, G.; Man, S.; Lawler, J.; Kerbel, R.S. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 12917-12922.
-
(2003)
Proc. Natl. Acad. Sci.
, vol.100
, pp. 12917-12922
-
-
Bocci, G.1
Francia, G.2
Man, S.3
Lawler, J.4
Kerbel, R.S.5
-
37
-
-
0036225350
-
Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: Antitumor activity and correlation with vascular endothelial growth factor levels
-
Colleoni, M.; Rocca, A.; Sandri, M.T.; Zorzino, L.; Masci, G.; Nole, F.; Peruzzotti, G.; Robertson, C.; Orlando, L.; Cinieri, S. et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 2002, 13, 73-80.
-
(2002)
Ann. Oncol.
, vol.13
, pp. 73-80
-
-
Colleoni, M.1
Rocca, A.2
Sandri, M.T.3
Zorzino, L.4
Masci, G.5
Nole, F.6
Peruzzotti, G.7
Robertson, C.8
Orlando, L.9
Cinieri, S.10
-
38
-
-
0035214416
-
Metronomic scheduling: The future of chemotherapy?
-
Gasparini, G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001, 2, 733-740.
-
(2001)
Lancet Oncol.
, vol.2
, pp. 733-740
-
-
Gasparini, G.1
-
39
-
-
0035144453
-
All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor
-
Kim, E.; Moore, J.; Huang, J.; Soffer, S.; Manley, C.A.; O'Toole, K.; Middlesworth, W.; Stolar, C.J.; Kandel, J.J.; Yamashiro, D.J. All angiogenesis is not the same: Distinct patterns of response to antiangiogenic therapy in experimental neuroblastoma and Wilms tumor. J. Pediatr. Surg. 2001, 36, 287-290.
-
(2001)
J. Pediatr. Surg.
, vol.36
, pp. 287-290
-
-
Kim, E.1
Moore, J.2
Huang, J.3
Soffer, S.4
Manley, C.A.5
O'Toole, K.6
Middlesworth, W.7
Stolar, C.J.8
Kandel, J.J.9
Yamashiro, D.J.10
-
40
-
-
0035206188
-
Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor
-
Soffer, S.Z.; Kim, E.; Moore, J.T.; Huang, J.; Yokoi, A.; Manley, C.; O'Toole, K.; Middlesworth, W.; Stolar, C.; Yamashiro, D. et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor. J. Pediatr. Surg. 2001, 36, 1781-1784.
-
(2001)
J. Pediatr. Surg.
, vol.36
, pp. 1781-1784
-
-
Soffer, S.Z.1
Kim, E.2
Moore, J.T.3
Huang, J.4
Yokoi, A.5
Manley, C.6
O'Toole, K.7
Middlesworth, W.8
Stolar, C.9
Yamashiro, D.10
-
41
-
-
19644376976
-
Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells
-
Beppu, K.; Nakamura, K.; Linehan, W.M.; Rapisarda, A.; Thiele, C.J. Topotecan blocks hypoxia-inducible factor-1 alpha and vascular endothelial growth factor expression induced by insulin-like growth factor-I in neuroblastoma cells. Cancer Res. 2005, 65, 4775-4781.
-
(2005)
Cancer Res.
, vol.65
, pp. 4775-4781
-
-
Beppu, K.1
Nakamura, K.2
Linehan, W.M.3
Rapisarda, A.4
Thiele, C.J.5
-
42
-
-
0034894341
-
Combination antiangiogenic therapy: Increased efficacy in a murine model of Wilms tumor
-
Soffer, S.Z.; Moore, J.T.; Kim, E.; Huang, J.; Yokoi, A.; Manley, C.; O'Toole, K.; Stolar, C.; Middlesworth, W.; Yamashiro, D.J. et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J. Pediatr. Surg. 2001, 36, 1177-1181.
-
(2001)
J. Pediatr. Surg.
, vol.36
, pp. 1177-1181
-
-
Soffer, S.Z.1
Moore, J.T.2
Kim, E.3
Huang, J.4
Yokoi, A.5
Manley, C.6
O'Toole, K.7
Stolar, C.8
Middlesworth, W.9
Yamashiro, D.J.10
-
43
-
-
0035987652
-
Topotecan is anti-angiogenic in experimental hepatoblastoma
-
McCrudden, K.W.; Yokoi, A.; Thosani, A.; Soffer, S.Z.; Kim, E.S.; Huang, J.; Manley, C.; O'Toole, K.; Yamashiro, D.J.; Kandel, J.J. et al. Topotecan is anti-angiogenic in experimental hepatoblastoma. J. Pediatr. Surg. 2002, 37, 857-861.
-
(2002)
J. Pediatr. Surg.
, vol.37
, pp. 857-861
-
-
McCrudden, K.W.1
Yokoi, A.2
Thosani, A.3
Soffer, S.Z.4
Kim, E.S.5
Huang, J.6
Manley, C.7
O'Toole, K.8
Yamashiro, D.J.9
Kandel, J.J.10
-
44
-
-
0042131613
-
Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis
-
Gately, S.; Kerbel, R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog. Exp. Tumor Res. 2003, 37, 179-192.
-
(2003)
Prog. Exp. Tumor Res.
, vol.37
, pp. 179-192
-
-
Gately, S.1
Kerbel, R.2
-
45
-
-
0036152447
-
Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts
-
Klement, G.; Huang, P.; Mayer, B.; Green, S.K.; Man, S.; Bohlen, P.; Hicklin, D.; Kerbel, R.S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 2002, 8, 221-232.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 221-232
-
-
Klement, G.1
Huang, P.2
Mayer, B.3
Green, S.K.4
Man, S.5
Bohlen, P.6
Hicklin, D.7
Kerbel, R.S.8
-
46
-
-
0035887463
-
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo
-
Bello, L.; Carrabba, G.; Giussani, C.; Lucini, V.; Cerutti, F.; Scaglione, F.; Landre, J.; Pluderi, M.; Tomei, G.; Villani, R. et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res. 2001, 61, 7501-7506.
-
(2001)
Cancer Res.
, vol.61
, pp. 7501-7506
-
-
Bello, L.1
Carrabba, G.2
Giussani, C.3
Lucini, V.4
Cerutti, F.5
Scaglione, F.6
Landre, J.7
Pluderi, M.8
Tomei, G.9
Villani, R.10
-
47
-
-
0026486664
-
Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
-
Teicher, B.A.; Sotomayor, E.A.; Huang, Z.D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992, 52, 6702-6704.
-
(1992)
Cancer Res.
, vol.52
, pp. 6702-6704
-
-
Teicher, B.A.1
Sotomayor, E.A.2
Huang, Z.D.3
-
48
-
-
0030920374
-
Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents
-
Kakeji, Y.; Teicher, B.A. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997, 15, 39-48.
-
(1997)
Invest New Drugs
, vol.15
, pp. 39-48
-
-
Kakeji, Y.1
Teicher, B.A.2
-
49
-
-
12244265088
-
Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease
-
Cervi, D.; Klement, G.; Stempak, D.; Baruchel, S.; Koki, A.; Ben David, Y. Targeting cyclooxygenase-2 reduces overt toxicity toward low-dose vinblastine and extends survival of juvenile mice with Friend disease. Clin. Cancer Res. 2005, 11, 712-719.
-
(2005)
Clin. Cancer Res.
, vol.11
, pp. 712-719
-
-
Cervi, D.1
Klement, G.2
Stempak, D.3
Baruchel, S.4
Koki, A.5
Ben David, Y.6
-
50
-
-
0031753296
-
Treatment of non-small-cell lung cancer with prolonged oral etoposide
-
Kakolyris, S.; Samonis, G.; Koukourakis, M.; Vlachonicolis, I.; Chalkiadakis, G.; Kalbakis, K.; Souglakos, I.; Agelaki, S.; Toloudis, P.; Georgoulias, V. Treatment of non-small-cell lung cancer with prolonged oral etoposide. Am. J. Clin. Oncol. 1998, 21, 505-508.
-
(1998)
Am. J. Clin. Oncol.
, vol.21
, pp. 505-508
-
-
Kakolyris, S.1
Samonis, G.2
Koukourakis, M.3
Vlachonicolis, I.4
Chalkiadakis, G.5
Kalbakis, K.6
Souglakos, I.7
Agelaki, S.8
Toloudis, P.9
Georgoulias, V.10
-
51
-
-
0031036177
-
Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
-
Rennelly, D.; Aghajanian, C.; Shapiro, F.; O'Flaherty, C.; McKenzie, M.; O'Connor, C.; Tong, W.; Norton, L.; Spriggs, D. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 1997, 15, 187-192.
-
(1997)
J. Clin. Oncol.
, vol.15
, pp. 187-192
-
-
Rennelly, D.1
Aghajanian, C.2
Shapiro, F.3
O'Flaherty, C.4
McKenzie, M.5
O'Connor, C.6
Tong, W.7
Norton, L.8
Spriggs, D.9
-
52
-
-
0141958313
-
Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma
-
Glode, L.M.; Barqawi, A.; Crighton, F.; Crawford, E.D.; Kerbel, R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer 2003, 98, 1643-1648.
-
(2003)
Cancer
, vol.98
, pp. 1643-1648
-
-
Glode, L.M.1
Barqawi, A.2
Crighton, F.3
Crawford, E.D.4
Kerbel, R.5
-
53
-
-
5344266706
-
Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC)
-
Nicolini, A.; Mancini, P.; Rerrari, P.; Anselmi, L.; Tartarelli, G.; Bonazzi, V.; Carpi, A.; Giardino, R. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC). Biomed. Pharmacother. 2004, 58, 447-450.
-
(2004)
Biomed. Pharmacother.
, vol.58
, pp. 447-450
-
-
Nicolini, A.1
Mancini, P.2
Rerrari, P.3
Anselmi, L.4
Tartarelli, G.5
Bonazzi, V.6
Carpi, A.7
Giardino, R.8
-
54
-
-
2342436921
-
Anti-angiogenic chemotherapy in central nervous system tumors
-
Kieran, M.W. Anti-angiogenic chemotherapy in central nervous system tumors. Cancer Treat. Res. 2004, 117, 337-349.
-
(2004)
Cancer Treat. Res.
, vol.117
, pp. 337-349
-
-
Kieran, M.W.1
-
55
-
-
23844471332
-
A Multicenter Phase II study of Irinotecan(CPT), Cisplatin(CIS), and Bevacizumab(BEV) in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma
-
Abstr.
-
Shah, M.A.; Ilson, D.; Ramanathan, R.K.; Levner, A.; D'Adamo, D.; Schwartz, L.; Casper, E.; Schwartz, G.K.; Kelsen, D.P. A Multicenter Phase II study of Irinotecan(CPT), Cisplatin(CIS), and Bevacizumab(BEV) in patients with Unresectable or Metastatic Gastric or Gastroesophageal Junction(GEJ) Adenocarcinoma. J. Clin. Oncol. 2005, 23, 4025 (Abstr.)
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 4025
-
-
Shah, M.A.1
Ilson, D.2
Ramanathan, R.K.3
Levner, A.4
D'Adamo, D.5
Schwartz, L.6
Casper, E.7
Schwartz, G.K.8
Kelsen, D.P.9
-
56
-
-
29444432612
-
Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial
-
Abstr.
-
Garcia. A.A.; Oza, A.M.; Hirte, H.; Fleming, G.; Tsao-Wei, D.; Roman, L.; Swenson, S.; Gandara, D.; Scudder, S.; Morgan, R. Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial. J. Clin. Oncol. 2005, 23, 5000 (Abstr.)
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 5000
-
-
Garcia, A.A.1
Oza, A.M.2
Hirte, H.3
Fleming, G.4
Tsao-Wei, D.5
Roman, L.6
Swenson, S.7
Gandara, D.8
Scudder, S.9
Morgan, R.10
-
57
-
-
0002972502
-
Acute Lymphoblastic Leukemia
-
Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia)
-
Margolin, J.F.; Poplack, D.G. Acute Lymphoblastic Leukemia. In Principles and Practice of Pediatric Oncology. Pizzo, P.A., Poplack, D.G., Eds. (Lippincott-Raven Publishers, Philadelphia, 1997), 409-461.
-
(1997)
Principles and Practice of Pediatric Oncology
, pp. 409-461
-
-
Margolin, J.F.1
Poplack, D.G.2
-
58
-
-
0033967199
-
Relapses of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children - A report from the French Society of Pediatric Oncology
-
Brugieres, L.; Quartier, P.; Le Deley, M.C.; Pacquement, H.; Perel, Y.; Bergeron, C.; Schmitt, C.; Landmann, J.; Patte, C.; Terrier-Lacombe, M.J. et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children - a report from the French Society of Pediatric Oncology. Ann. Oncol. 2000, 11, 53-58.
-
(2000)
Ann. Oncol.
, vol.11
, pp. 53-58
-
-
Brugieres, L.1
Quartier, P.2
Le Deley, M.C.3
Pacquement, H.4
Perel, Y.5
Bergeron, C.6
Schmitt, C.7
Landmann, J.8
Patte, C.9
Terrier-Lacombe, M.J.10
-
59
-
-
33745764554
-
Safety and Pharmacokinetics of Temozolomide using a Dose Escalation Metronomic Schedule in Recurrent Pediatric Brain Tumors
-
In press
-
Baruchel, S.; Diezi, M.; Margrave, D.; Stempak, D.; Gammon, J.; Moghrabi, A.; Coppes, M.; Fernandez, C.V.; Bouffet, E. Safety and Pharmacokinetics of Temozolomide using a Dose Escalation Metronomic Schedule in Recurrent Pediatric Brain Tumors. In press, European Journal of Cancer.
-
European Journal of Cancer
-
-
Baruchel, S.1
Diezi, M.2
Margrave, D.3
Stempak, D.4
Gammon, J.5
Moghrabi, A.6
Coppes, M.7
Fernandez, C.V.8
Bouffet, E.9
-
60
-
-
0036256785
-
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors
-
Sterba, J.; Pavelka, Z.; Slampa, P. Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors. Neoplasma 2002, 49, 117-120.
-
(2002)
Neoplasma
, vol.49
, pp. 117-120
-
-
Sterba, J.1
Pavelka, Z.2
Slampa, P.3
-
61
-
-
0038559892
-
Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas
-
Kuo, D.J.; Weiner, H.L.; Wisoff, J.; Miller, D.C.; Knopp, E.A.; Finlay, J.L. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J. Pediatr. Hematol. Oncol. 2003, 25, 372-378.
-
(2003)
J. Pediatr. Hematol. Oncol.
, vol.25
, pp. 372-378
-
-
Kuo, D.J.1
Weiner, H.L.2
Wisoff, J.3
Miller, D.C.4
Knopp, E.A.5
Finlay, J.L.6
-
63
-
-
24344485994
-
CYP2C9 genotype: Impact on celecoxib safety and pharmacokinetics in a pediatric patient
-
in press
-
Stempak, D.; Bukaveckas, B.L.; Linder, M.; Koren, G.; Baruchel, S. CYP2C9 genotype: impact on celecoxib safety and pharmacokinetics in a pediatric patient. Clin. Pharmacol. Ther. 2005, in press.
-
(2005)
Clin. Pharmacol. Ther.
-
-
Stempak, D.1
Bukaveckas, B.L.2
Linder, M.3
Koren, G.4
Baruchel, S.5
-
64
-
-
20144365496
-
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
-
Solomon, S.D.; McMurray, J.J.; Pfeffer, M.A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W.F.; Zauber, A.; Hawk, E.; Bertagnolli, M. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. N. Engl. J. Med. 2005.
-
(2005)
N. Engl. J. Med.
-
-
Solomon, S.D.1
McMurray, J.J.2
Pfeffer, M.A.3
Wittes, J.4
Fowler, R.5
Finn, P.6
Anderson, W.F.7
Zauber, A.8
Hawk, E.9
Bertagnolli, M.10
-
65
-
-
13944264243
-
Don't throw out the baby with the bathwater!
-
Kamen, B.; Kieran, M. Don't throw out the baby with the bathwater! J. Pediatr. Hematol. Oncol. 2005, 27, 59-60.
-
(2005)
J. Pediatr. Hematol. Oncol.
, vol.27
, pp. 59-60
-
-
Kamen, B.1
Kieran, M.2
-
66
-
-
13944274200
-
Modulation of celecoxib pharmacokinetics by food in pediatric patients
-
Stempak, D.; Gammon, J.; Halton, J.; Champagne, M.; Koren, G.; Baruchel, S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin. Pharmacol. Ther. 2005, 77, 226-228.
-
(2005)
Clin. Pharmacol. Ther.
, vol.77
, pp. 226-228
-
-
Stempak, D.1
Gammon, J.2
Halton, J.3
Champagne, M.4
Koren, G.5
Baruchel, S.6
-
67
-
-
0842312987
-
Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors
-
Bowers, D.C.; Aquino, V.M.; Leavey, P.J.; Bash, R.O.; Journeycake, J.M.; Tomlinson, G.; Mulne, A.F.; Haynes, H.J.; Winick, N.J. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr. Blood Cancer 2004, 42, 93-98.
-
(2004)
Pediatr. Blood Cancer
, vol.42
, pp. 93-98
-
-
Bowers, D.C.1
Aquino, V.M.2
Leavey, P.J.3
Bash, R.O.4
Journeycake, J.M.5
Tomlinson, G.6
Mulne, A.F.7
Haynes, H.J.8
Winick, N.J.9
-
68
-
-
1542267857
-
Oral etoposide for recurrent/progressive sarcomas of childhood
-
Kebudi, R.; Gorgun, O.; Ayan, I. Oral etoposide for recurrent/progressive sarcomas of childhood. Pediatr. Blood Cancer 2004, 42, 320-324.
-
(2004)
Pediatr. Blood Cancer
, vol.42
, pp. 320-324
-
-
Kebudi, R.1
Gorgun, O.2
Ayan, I.3
-
69
-
-
0034796595
-
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
-
Jain, R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001, 7, 987-989.
-
(2001)
Nat. Med.
, vol.7
, pp. 987-989
-
-
Jain, R.K.1
-
70
-
-
12344296657
-
A surrogate marker to monitor angiogenesis at last
-
Schneider, M.; Tjwa, M.; Carmeliet, P. A surrogate marker to monitor angiogenesis at last. Cancer Cell 2005, 7, 3-4.
-
(2005)
Cancer Cell
, vol.7
, pp. 3-4
-
-
Schneider, M.1
Tjwa, M.2
Carmeliet, P.3
-
71
-
-
19944432454
-
Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis
-
Shaked, Y.; Bertolini, F.; Man, S.; Rogers, M.S.; Cervi, D.; Foutz, T.; Rawn, K.; Voskas, D.; Dumont, D.J.; Ben David, Y. et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005, 7, 101-111.
-
(2005)
Cancer Cell
, vol.7
, pp. 101-111
-
-
Shaked, Y.1
Bertolini, F.2
Man, S.3
Rogers, M.S.4
Cervi, D.5
Foutz, T.6
Rawn, K.7
Voskas, D.8
Dumont, D.J.9
Ben David, Y.10
-
72
-
-
18944379083
-
Can a rational design for metronomic chemotherapy dosing be devised?
-
Maraveyas, A.; Lam, T.; Hetherington, J.W.; Greenman, J. Can a rational design for metronomic chemotherapy dosing be devised? Br. J. Cancer 2005, 92, 1588-1590.
-
(2005)
Br. J. Cancer
, vol.92
, pp. 1588-1590
-
-
Maraveyas, A.1
Lam, T.2
Hetherington, J.W.3
Greenman, J.4
-
73
-
-
0002466429
-
Drug Therapeutics in the Infant and Child
-
Yaffe, S.J., Aranda, J.V., Eds. (Saunders, Philadelphia)
-
Kauffman, R.E. Drug Therapeutics in the Infant and Child. In Pediatric Pharmacology: Therapeutic Principles in Practice. Yaffe, S.J., Aranda, J.V., Eds. (Saunders, Philadelphia, 1992), 212-219.
-
(1992)
Pediatric Pharmacology: Therapeutic Principles in Practice
, pp. 212-219
-
-
Kauffman, R.E.1
-
74
-
-
0028567081
-
Pharmacokinetic variability in the adolescent: Implications of body size and organ function for dosage regimen design
-
Rodman, J.H. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J. Adolesc. Health 1994, 15, 654-662.
-
(1994)
J. Adolesc. Health
, vol.15
, pp. 654-662
-
-
Rodman, J.H.1
-
75
-
-
0024835315
-
Clinical pharmacokinetics in infants and children. A reappraisal
-
Kearns, G.L.; Reed, M.D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet. 1989, 17 Suppl 1, 29-67.
-
(1989)
Clin. Pharmacokinet.
, vol.17
, Issue.1 SUPPL.
, pp. 29-67
-
-
Kearns, G.L.1
Reed, M.D.2
-
76
-
-
0034033851
-
Human cytochrome P450 maximal activities in pediatric versus adult liver
-
Blanco, J.G.; Harrison, P.L.; Evans, W.E.; Relling, M.V. Human cytochrome P450 maximal activities in pediatric versus adult liver. Drug Metab Dispos. 2000, 28, 379-382.
-
(2000)
Drug Metab Dispos.
, vol.28
, pp. 379-382
-
-
Blanco, J.G.1
Harrison, P.L.2
Evans, W.E.3
Relling, M.V.4
-
77
-
-
0013332243
-
Pharmacokinetics in Children
-
Azarnoff, D.L., Ed. (Churchill Livingstone, New York)
-
Boreus, L.O. Pharmacokinetics in Children. In Principles of Pediatric Pharmacology. Azarnoff, D.L., Ed. (Churchill Livingstone, New York, 1982), 135-175.
-
(1982)
Principles of Pediatric Pharmacology
, pp. 135-175
-
-
Boreus, L.O.1
-
78
-
-
0034092011
-
Tumor angiogenesis: Past, present and the near future
-
Kerbel, R.S. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000, 21, 505-515.
-
(2000)
Carcinogenesis
, vol.21
, pp. 505-515
-
-
Kerbel, R.S.1
-
79
-
-
0035253586
-
Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
-
Margolin, K.; Gordon, M.S.; Holmgren, E.; Gaudreault, J.; Novotny, W.; Fyfe, G.; Adelman, D.; Stalter, S.; Breed, J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001, 19, 851-856.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 851-856
-
-
Margolin, K.1
Gordon, M.S.2
Holmgren, E.3
Gaudreault, J.4
Novotny, W.5
Fyfe, G.6
Adelman, D.7
Stalter, S.8
Breed, J.9
-
80
-
-
0037440123
-
Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors
-
Thomas, J.P.; Arzoomanian, R.Z.; Alberti, D.; Marnocha, R.; Lee, F.; Friedl, A.; Tutsch, K.; Dresen, A.; Geiger, P.; Pluda, J. et al. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2003, 21, 223-231.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 223-231
-
-
Thomas, J.P.1
Arzoomanian, R.Z.2
Alberti, D.3
Marnocha, R.4
Lee, F.5
Friedl, A.6
Tutsch, K.7
Dresen, A.8
Geiger, P.9
Pluda, J.10
-
81
-
-
0034000338
-
Prognostic value of vascular endothelial growth factor in breast cancer
-
Gasparini, G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000, 5 Suppl 1, 37-44.
-
(2000)
Oncologist
, vol.5
, Issue.1 SUPPL.
, pp. 37-44
-
-
Gasparini, G.1
-
82
-
-
0031409282
-
Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
-
Dosquet, C.; Coudert, M.C.; Lepage, E.; Cabane, J.; Richard, F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin. Cancer Res. 1997, 3, 2451-2458.
-
(1997)
Clin. Cancer Res.
, vol.3
, pp. 2451-2458
-
-
Dosquet, C.1
Coudert, M.C.2
Lepage, E.3
Cabane, J.4
Richard, F.5
-
83
-
-
0030997316
-
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients
-
Dirix, L.Y.; Vermeulen, P.B.; Pawinski, A.; Prove, A.; Benoy, I.; De Pooter, C.; Martin, M.; van Oosterom, A.T. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br. J. Cancer 1997, 76, 238-243.
-
(1997)
Br. J. Cancer
, vol.76
, pp. 238-243
-
-
Dirix, L.Y.1
Vermeulen, P.B.2
Pawinski, A.3
Prove, A.4
Benoy, I.5
De Pooter, C.6
Martin, M.7
Van Oosterom, A.T.8
-
84
-
-
0032845702
-
Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma
-
Bertolini, F.; Paolucci, M.; Peccatori, F.; Cinieri, S.; Agazzi, A.; Ferrucci, P.F.; Cocorocchio, E.; Goldhirsch, A.; Martinelli, G. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br. J. Haematol. 1999, 106, 504-509.
-
(1999)
Br. J. Haematol.
, vol.106
, pp. 504-509
-
-
Bertolini, F.1
Paolucci, M.2
Peccatori, F.3
Cinieri, S.4
Agazzi, A.5
Ferrucci, P.F.6
Cocorocchio, E.7
Goldhirsch, A.8
Martinelli, G.9
-
85
-
-
0035865450
-
Clinical implications of circulating angiogenic factors in cancer patients
-
Poon, R.T.; Fan, S.T.; Wong, J. Clinical implications of circulating angiogenic factors in cancer patients. J. Clin. Oncol. 2001, 19, 1207-1225.
-
(2001)
J. Clin. Oncol.
, vol.19
, pp. 1207-1225
-
-
Poon, R.T.1
Fan, S.T.2
Wong, J.3
-
86
-
-
0034674895
-
Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis
-
Byrne, G.J.; Ghellal, A.; Iddon, J.; Blann, A.D.; Venizelos, V.; Kumar, S.; Howell, A.; Bundred, N.J. Serum soluble vascular cell adhesion molecule-1: role as a surrogate marker of angiogenesis. J. Natl. Cancer Inst. 2000, 92, 1329-1336.
-
(2000)
J. Natl. Cancer Inst.
, vol.92
, pp. 1329-1336
-
-
Byrne, G.J.1
Ghellal, A.2
Iddon, J.3
Blann, A.D.4
Venizelos, V.5
Kumar, S.6
Howell, A.7
Bundred, N.J.8
-
87
-
-
3042670492
-
Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma
-
Poon, R.T.; Chung, K.K.; Cheung, S.T.; Lau, C.P.; Tong, S.W.; Leung, K.L.; Yu, W.C.; Tuszynski, G.P.; Fan, S.T. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin. Cancer Res. 2004, 10, 4150-4157.
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 4150-4157
-
-
Poon, R.T.1
Chung, K.K.2
Cheung, S.T.3
Lau, C.P.4
Tong, S.W.5
Leung, K.L.6
Yu, W.C.7
Tuszynski, G.P.8
Fan, S.T.9
-
88
-
-
0034488630
-
Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer
-
Feldman, A.L.; Tamarkin, L.; Paciotti, G.F.; Simpson, B.W.; Linehan, W.M.; Yang, J.C.; Fogler, W.E.; Turner, E.M.; Alexander, H.R.; Jr.; Libutti, S.K. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin. Cancer Res. 2000, 6, 4628-4634.
-
(2000)
Clin. Cancer Res.
, vol.6
, pp. 4628-4634
-
-
Feldman, A.L.1
Tamarkin, L.2
Paciotti, G.F.3
Simpson, B.W.4
Linehan, W.M.5
Yang, J.C.6
Fogler, W.E.7
Turner, E.M.8
Alexander Jr., H.R.9
Libutti, S.K.10
-
89
-
-
0028916239
-
Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients
-
Lin, R.Y.; Argenta, P.A.; Sullivan, K.M.; Adzick, N.S. Diagnostic and prognostic role of basic fibroblast growth factor in Wilms' tumor patients. Clin Cancer Res. 1995, 1, 327-331.
-
(1995)
Clin Cancer Res.
, vol.1
, pp. 327-331
-
-
Lin, R.Y.1
Argenta, P.A.2
Sullivan, K.M.3
Adzick, N.S.4
-
90
-
-
0036168594
-
Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels
-
Jeha, S.; Smith, F.O.; Estey, E.; Shen, Y.; Liu, D.; Manshouri, T.; Albitar, M. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk. Res. 2002, 26, 399-402.
-
(2002)
Leuk. Res.
, vol.26
, pp. 399-402
-
-
Jeha, S.1
Smith, F.O.2
Estey, E.3
Shen, Y.4
Liu, D.5
Manshouri, T.6
Albitar, M.7
-
91
-
-
0036718433
-
Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients
-
de Bont, E.S.; Fidler, V.; Meeuwsen, T.; Scherpen, F.; Hahlen, K.; Kamps, W.A. Vascular endothelial growth factor secretion is an independent prognostic factor for relapse-free survival in pediatric acute myeloid leukemia patients. Clin. Cancer Res. 2002, 8, 2856-2861.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 2856-2861
-
-
De Bont, E.S.1
Fidler, V.2
Meeuwsen, T.3
Scherpen, F.4
Hahlen, K.5
Kamps, W.A.6
-
92
-
-
0034905950
-
Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
-
Tabone, M.D.; Landman-Parker, J.; Arcil, B.; Coudert, M.C.; Gerota, I.; Benbunan, M.; Leverger, G.; Dosquet, C. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin. Cancer Res. 2001, 7, 538-543.
-
(2001)
Clin. Cancer Res.
, vol.7
, pp. 538-543
-
-
Tabone, M.D.1
Landman-Parker, J.2
Arcil, B.3
Coudert, M.C.4
Gerota, I.5
Benbunan, M.6
Leverger, G.7
Dosquet, C.8
-
93
-
-
0035371933
-
Quantification of angiogenesis stimulators in children with solid malignancies
-
Pavlakovic, H.; Von, S.V.; Rossler, J.; Koscielniak, E.; Havers, W.; Schweigerer, L. Quantification of angiogenesis stimulators in children with solid malignancies. Int. J. Cancer 2001, 92, 756-760.
-
(2001)
Int. J. Cancer
, vol.92
, pp. 756-760
-
-
Pavlakovic, H.1
Von, S.V.2
Rossler, J.3
Koscielniak, E.4
Havers, W.5
Schweigerer, L.6
-
94
-
-
1642368865
-
Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression
-
Hamano, Y.; Sugimoto, H.; Soubasakos, M.A.; Kieran, M.; Olsen, B.R.; Lawler, J.; Sudhakar, A.; Kalluri, R. Thrombospondin-1 associated with tumor microenvironment contributes to low-dose cyclophosphamide-mediated endothelial cell apoptosis and tumor growth suppression. Cancer Res. 2004, 64, 1570-1574.
-
(2004)
Cancer Res.
, vol.64
, pp. 1570-1574
-
-
Hamano, Y.1
Sugimoto, H.2
Soubasakos, M.A.3
Kieran, M.4
Olsen, B.R.5
Lawler, J.6
Sudhakar, A.7
Kalluri, R.8
-
95
-
-
4644271546
-
Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies
-
Bocci, G.; Man, S.; Green, S.K.; Francia, G.; Ebos, J.M.; du Manoir, J.M.; Weinerman, A.; Emmenegger, U.; Ma, L.; Thorpe, P. et al. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004, 64, 6616-6625.
-
(2004)
Cancer Res.
, vol.64
, pp. 6616-6625
-
-
Bocci, G.1
Man, S.2
Green, S.K.3
Francia, G.4
Ebos, J.M.5
Du Manoir, J.M.6
Weinerman, A.7
Emmenegger, U.8
Ma, L.9
Thorpe, P.10
-
96
-
-
0037106261
-
Phase I study of recombinant human endostatin in patients with advanced solid tumors
-
Herbst, R.S.; Hess, K.R.; Tran, H.T.; Tseng, J.E.; Mullani, N.A.; Charnsangavej, C.; Madden, T.; Davis, D.W.; McConkey, D.J.; O'Reilly, M.S. et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol. 2002, 20, 3792-3803.
-
(2002)
J. Clin. Oncol.
, vol.20
, pp. 3792-3803
-
-
Herbst, R.S.1
Hess, K.R.2
Tran, H.T.3
Tseng, J.E.4
Mullani, N.A.5
Charnsangavej, C.6
Madden, T.7
Davis, D.W.8
McConkey, D.J.9
O'Reilly, M.S.10
-
97
-
-
0041589524
-
Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
-
Bertolini, F.; Paul, S.; Mancuso, P.; Monestiroli, S.; Gobbi, A.; Shaked, Y.; Kerbel, R.S. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res. 2003, 63, 4342-4346.
-
(2003)
Cancer Res.
, vol.63
, pp. 4342-4346
-
-
Bertolini, F.1
Paul, S.2
Mancuso, P.3
Monestiroli, S.4
Gobbi, A.5
Shaked, Y.6
Kerbel, R.S.7
-
98
-
-
0033529618
-
Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
-
Asahara, T.; Masuda, H.; Takahashi, T.; Kalka, C.; Pastore, C.; Silver, M.; Kearne, M.; Magner, M.; Isner, J.M. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 1999, 85, 221-228.
-
(1999)
Circ. Res.
, vol.85
, pp. 221-228
-
-
Asahara, T.1
Masuda, H.2
Takahashi, T.3
Kalka, C.4
Pastore, C.5
Silver, M.6
Kearne, M.7
Magner, M.8
Isner, J.M.9
-
99
-
-
0033565540
-
VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells
-
Asahara, T.; Takahashi, T.; Masuda, H.; Kalka, C.; Chen, D.; Iwaguro, H.; Inai, Y.; Silver, M.; Isner, J.M. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 1999, 18, 3964-3972.
-
(1999)
EMBO J.
, vol.18
, pp. 3964-3972
-
-
Asahara, T.1
Takahashi, T.2
Masuda, H.3
Kalka, C.4
Chen, D.5
Iwaguro, H.6
Inai, Y.7
Silver, M.8
Isner, J.M.9
-
100
-
-
0036831559
-
Vascular and haematopoietic stem cells: Novel targets for antiangiogenesis therapy?
-
Rafii, S.; Lyden, D.; Benezra, R.; Hattori, K.; Heissig, B. Vascular and haematopoietic stem cells: novel targets for antiangiogenesis therapy? Nat. Rev. Cancer 2002, 2, 826-835.
-
(2002)
Nat. Rev. Cancer
, vol.2
, pp. 826-835
-
-
Rafii, S.1
Lyden, D.2
Benezra, R.3
Hattori, K.4
Heissig, B.5
-
101
-
-
0035160312
-
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
-
Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
-
(2001)
Nat. Med.
, vol.7
, pp. 1194-1201
-
-
Lyden, D.1
Hattori, K.2
Dias, S.3
Costa, C.4
Blaikie, P.5
Butros, L.6
Chadburn, A.7
Heissig, B.8
Marks, W.9
Witte, L.10
-
102
-
-
0142258071
-
Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors
-
Sikder, H.; Huso, D.L.; Zhang, H.; Wang, B.; Ryu, B.; Hwang, S.T.; Powell, J.D.; Alani, R.M. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003, 4, 291-299.
-
(2003)
Cancer Cell
, vol.4
, pp. 291-299
-
-
Sikder, H.1
Huso, D.L.2
Zhang, H.3
Wang, B.4
Ryu, B.5
Hwang, S.T.6
Powell, J.D.7
Alani, R.M.8
-
103
-
-
0003138605
-
Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions
-
Padera, T.P.; Stoll, B.R.; So, P.T.; Jain, R.K. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol. Imaging 2002, 1, 9-15.
-
(2002)
Mol. Imaging
, vol.1
, pp. 9-15
-
-
Padera, T.P.1
Stoll, B.R.2
So, P.T.3
Jain, R.K.4
-
104
-
-
0346365369
-
Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells
-
Schuch, G.; Heymach, J.V.; Nomi, M.; Machluf, M.; Force, J.; Atala, A.; Eder, J.P.; Jr.; Folkman, J.; Soker, S. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res. 2003, 63, 8345-8350.
-
(2003)
Cancer Res.
, vol.63
, pp. 8345-8350
-
-
Schuch, G.1
Heymach, J.V.2
Nomi, M.3
Machluf, M.4
Force, J.5
Atala, A.6
Eder Jr., J.P.7
Folkman, J.8
Soker, S.9
-
105
-
-
11144354392
-
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
-
Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V. et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145-147.
-
(2004)
Nat. Med.
, vol.10
, pp. 145-147
-
-
Willett, C.G.1
Boucher, Y.2
Di Tomaso, E.3
Duda, D.G.4
Munn, L.L.5
Tong, R.T.6
Chung, D.C.7
Sahani, D.V.8
Kalva, S.P.9
Kozin, S.V.10
-
106
-
-
0035383784
-
Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
-
Mancuso, P.; Burlini, A.; Pruneri, G.; Goldhirsch, A.; Martinelli, G.; Bertolini, F. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 2001, 97, 3658-3661.
-
(2001)
Blood
, vol.97
, pp. 3658-3661
-
-
Mancuso, P.1
Burlini, A.2
Pruneri, G.3
Goldhirsch, A.4
Martinelli, G.5
Bertolini, F.6
-
107
-
-
0035360833
-
Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma
-
Monestiroli, S.; Mancuso, P.; Burlini, A.; Pruneri, G.; Dell'Agnola, C.; Gobbi, A.; Martinelli, G.; Bertolini, F. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. Cancer Res. 2001, 61, 4341-4344.
-
(2001)
Cancer Res.
, vol.61
, pp. 4341-4344
-
-
Monestiroli, S.1
Mancuso, P.2
Burlini, A.3
Pruneri, G.4
Dell'Agnola, C.5
Gobbi, A.6
Martinelli, G.7
Bertolini, F.8
-
108
-
-
0035793330
-
Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells
-
Gill, M.; Dias, S.; Hattori, K.; Rivera, M.L.; Hicklin, D.; Witte, L.; Girardi, L.; Yurt, R.; Himel, H.; Rafii, S. Vascular trauma induces rapid but transient mobilization of VEGFR2(+)AC133(+) endothelial precursor cells. Circ. Res. 2001, 88, 167-174.
-
(2001)
Circ. Res.
, vol.88
, pp. 167-174
-
-
Gill, M.1
Dias, S.2
Hattori, K.3
Rivera, M.L.4
Hicklin, D.5
Witte, L.6
Girardi, L.7
Yurt, R.8
Himel, H.9
Rafii, S.10
-
109
-
-
0031019745
-
Isolation of putative progenitor endothelial cells for angiogenesis
-
Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der, Z.R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, J.M. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275, 964-967.
-
(1997)
Science
, vol.275
, pp. 964-967
-
-
Asahara, T.1
Murohara, T.2
Sullivan, A.3
Silver, M.4
Van Der, Z.R.5
Li, T.6
Witzenbichler, B.7
Schatteman, G.8
Isner, J.M.9
-
110
-
-
0033989026
-
Origins of circulating endothelial cells and endothelial outgrowth from blood
-
Lin, Y.; Weisdorf, D.J.; Solovey, A.; Hebbel, R.P. Origins of circulating endothelial cells and endothelial outgrowth from blood. J. Clin. Invest. 2000, 105, 71-77.
-
(2000)
J. Clin. Invest.
, vol.105
, pp. 71-77
-
-
Lin, Y.1
Weisdorf, D.J.2
Solovey, A.3
Hebbel, R.P.4
-
111
-
-
12244271051
-
Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors
-
Capillo, M.; Mancuso, P.; Gobbi, A.; Monestiroli, S.; Pruneri, G.; Dell'Agnola, C.; Martinelli, G.; Shultz, L.; Bertolini, F. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin. Cancer Res. 2003, 9, 377-382.
-
(2003)
Clin. Cancer Res.
, vol.9
, pp. 377-382
-
-
Capillo, M.1
Mancuso, P.2
Gobbi, A.3
Monestiroli, S.4
Pruneri, G.5
Dell'Agnola, C.6
Martinelli, G.7
Shultz, L.8
Bertolini, F.9
-
112
-
-
85047686759
-
Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma
-
Sussman, L.K.; Upalakalin, J.N.; Roberts, M.J.; Kocher, O.; Benjamin, L.E. Blood markers for vasculogenesis increase with tumor progression in patients with breast carcinoma. Cancer Biol. Ther. 2003, 2, 255-256.
-
(2003)
Cancer Biol. Ther.
, vol.2
, pp. 255-256
-
-
Sussman, L.K.1
Upalakalin, J.N.2
Roberts, M.J.3
Kocher, O.4
Benjamin, L.E.5
-
113
-
-
0942277099
-
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
-
Beerepoot, L.V.; Mehra, N.; Vermaat, J.S.; Zonnenberg, B.A.; Gebbink, M.F.; Voest, E.E. Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann. Oncol. 2004, 15, 139-145.
-
(2004)
Ann. Oncol.
, vol.15
, pp. 139-145
-
-
Beerepoot, L.V.1
Mehra, N.2
Vermaat, J.S.3
Zonnenberg, B.A.4
Gebbink, M.F.5
Voest, E.E.6
-
114
-
-
3042523515
-
Assessing tumor angiogenesis: Increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells
-
Rabascio, C.; Muratori, E.; Mancuso, P.; Calleri, A.; Raia, V.; Foutz, T.; Cinieri, S.; Veronesi, G.; Pruneri, G.; Lampertico, P. et al. Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. Cancer Res. 2004, 64, 4373-4377.
-
(2004)
Cancer Res.
, vol.64
, pp. 4373-4377
-
-
Rabascio, C.1
Muratori, E.2
Mancuso, P.3
Calleri, A.4
Raia, V.5
Foutz, T.6
Cinieri, S.7
Veronesi, G.8
Pruneri, G.9
Lampertico, P.10
-
115
-
-
0033986273
-
Circulating endothelial precursors: Mystery, reality, and promise
-
Rafii, S. Circulating endothelial precursors: mystery, reality, and promise. J. Clin. Invest. 2000, 105, 17-19.
-
(2000)
J. Clin. Invest.
, vol.105
, pp. 17-19
-
-
Rafii, S.1
-
116
-
-
0035160312
-
Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
-
Lyden, D.; Hattori, K.; Dias, S.; Costa, C.; Blaikie, P.; Butros, L.; Chadburn, A.; Heissig, B.; Marks, W.; Witte, L. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7, 1194-1201.
-
(2001)
Nat. Med.
, vol.7
, pp. 1194-1201
-
-
Lyden, D.1
Hattori, K.2
Dias, S.3
Costa, C.4
Blaikie, P.5
Butros, L.6
Chadburn, A.7
Heissig, B.8
Marks, W.9
Witte, L.10
-
117
-
-
0036848878
-
Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo
-
Bolontrade, M.F.; Zhou, R.R.; Kleinerman, E.S. Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clin. Cancer Res. 2002, 8, 3622-3627.
-
(2002)
Clin. Cancer Res.
, vol.8
, pp. 3622-3627
-
-
Bolontrade, M.F.1
Zhou, R.R.2
Kleinerman, E.S.3
-
118
-
-
0037011654
-
Induction of vasculogenesis in breast cancer models
-
Shirakawa, K.; Furuhata, S.; Watanabe, I.; Hayase, H.; Shimizu, A.; Ikarashi, Y.; Yoshida, T.; Terada, M.; Hashimoto, D.; Wakasugi, H. Induction of vasculogenesis in breast cancer models. Br. J. Cancer 2002, 87, 1454-1461.
-
(2002)
Br. J. Cancer
, vol.87
, pp. 1454-1461
-
-
Shirakawa, K.1
Furuhata, S.2
Watanabe, I.3
Hayase, H.4
Shimizu, A.5
Ikarashi, Y.6
Yoshida, T.7
Terada, M.8
Hashimoto, D.9
Wakasugi, H.10
-
119
-
-
0037967272
-
Tumorigenesis and the angiogenic switch
-
Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3, 401-410.
-
(2003)
Nat. Rev. Cancer
, vol.3
, pp. 401-410
-
-
Bergers, G.1
Benjamin, L.E.2
-
120
-
-
23844483271
-
Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
-
Bocci, G.; Tuccori, M.; Emmenegger, U.; Liguori, V.; Falcone, A.; Kerbel, R.S.; Del Tacca, M. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 2005.
-
(2005)
Ann. Oncol.
-
-
Bocci, G.1
Tuccori, M.2
Emmenegger, U.3
Liguori, V.4
Falcone, A.5
Kerbel, R.S.6
Del Tacca, M.7
-
121
-
-
33745307192
-
Chapter 12 - New Developmental Therapies
-
Abeloff, M.D., Ed. (Churchill Livingstone, Inc.)
-
Marshal, J.L.; Rizvi, N.A.; Bhargava, P.; Wojtoqicz-Praga, S.; Hawkins, M.J. Chapter 12 - New Developmental Therapies. In Clinical Oncology. Abeloff, M.D., Ed. (Churchill Livingstone, Inc.; 2000), 242-251.
-
(2000)
Clinical Oncology
, pp. 242-251
-
-
Marshal, J.L.1
Rizvi, N.A.2
Bhargava, P.3
Wojtoqicz-Praga, S.4
Hawkins, M.J.5
-
122
-
-
23944470359
-
Prospects for therapeutic inhibition of neuroblastoma angiogenesis
-
Shusterman, S.; Maris, J.M. Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett. 2005.
-
(2005)
Cancer Lett.
-
-
Shusterman, S.1
Maris, J.M.2
-
123
-
-
2542539735
-
A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens
-
Emmenegger, U.; Man, S.; Shaked, Y.; Francia, G.; Wong, J.W.; Hicklin, D.J.; Kerbel, R.S. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004, 64, 3994-4000.
-
(2004)
Cancer Res.
, vol.64
, pp. 3994-4000
-
-
Emmenegger, U.1
Man, S.2
Shaked, Y.3
Francia, G.4
Wong, J.W.5
Hicklin, D.J.6
Kerbel, R.S.7
-
124
-
-
1442283179
-
Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: A toxicity with therapeutic implications
-
Su, Y.B.; Sohn, S.; Krown, S.E.; Livingston, P.O.; Wolchok, J.D.; Quinn, C.; Williams, L.; Foster, T.; Sepkowitz, K.A.; Chapman, P.B. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J. Clin. Oncol. 2004, 22, 610-616.
-
(2004)
J. Clin. Oncol.
, vol.22
, pp. 610-616
-
-
Su, Y.B.1
Sohn, S.2
Krown, S.E.3
Livingston, P.O.4
Wolchok, J.D.5
Quinn, C.6
Williams, L.7
Foster, T.8
Sepkowitz, K.A.9
Chapman, P.B.10
-
125
-
-
14944377007
-
Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma
-
Su, Y.W.; Chang, M.C.; Chiang, M.F.; Hsieh, R.K. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J. Neurooncol. 2005, 71, 315-318.
-
(2005)
J. Neurooncol.
, vol.71
, pp. 315-318
-
-
Su, Y.W.1
Chang, M.C.2
Chiang, M.F.3
Hsieh, R.K.4
-
126
-
-
0038376001
-
Imaging of angiogenesis: From microscope to clinic
-
McDonald, D.M.; Choyke, P.L. Imaging of angiogenesis: from microscope to clinic. Nat. Med. 2003, 9, 713-725.
-
(2003)
Nat. Med.
, vol.9
, pp. 713-725
-
-
McDonald, D.M.1
Choyke, P.L.2
-
127
-
-
0036593385
-
Angiogenesis modulation in cancer research: Novel clinical approaches
-
Cristofanilli, M.; Charnsangavej, C.; Hortobagyi, G.N. Angiogenesis modulation in cancer research: novel clinical approaches. Nat. Rev. Drug Discov. 2002, 1, 415-426.
-
(2002)
Nat. Rev. Drug Discov.
, vol.1
, pp. 415-426
-
-
Cristofanilli, M.1
Charnsangavej, C.2
Hortobagyi, G.N.3
-
128
-
-
0347615101
-
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies
-
Morgan, B.; Thomas, A.L.; Drevs, J.; Hennig, J.; Buchert, M.; Jivan, A.; Horsfield, M.A.; Mross, K.; Ball, H.A.; Lee, L. et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003, 21, 3955-3964.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3955-3964
-
-
Morgan, B.1
Thomas, A.L.2
Drevs, J.3
Hennig, J.4
Buchert, M.5
Jivan, A.6
Horsfield, M.A.7
Mross, K.8
Ball, H.A.9
Lee, L.10
|